Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial

Authors

M. Hennessy, Cancer Research - UCC, Cork, Ireland
C. Gatsonis, Brown University, Providence, RI
H. Jacene, Dana-Farber Cancer Institute, Boston, MA
R.M. Connolly, Cancer Research - UCC, Cork, Ireland
B.L. Burnette, Saint Vincent Hospital, Green Bay, WI
E.M. Stringer-Reasor, Brown University, Providence, MA
J. Romanoff, Brown University, Providence, MA
A. Taurone, Brown University, Providence, MA
C.C. O'Sullivan, Mayo Clinic, Rochester, MN
H.T. Le-Petross, Anderson Cancer Center, Houston, TX
C.L. Heath, UCSF Medical Center, San Francisco, CA
V. Stearns, Weill Cornell Medicine, New York, NY
A.M. Fowler, University of Wisconsin, Madison, WI
Shou-Ching Tang, LSU Health Sciences Center - New OrleansFollow
K. Sepulveda, Ben Taub General Hospital, Houston, TX
A. DeMichele, University of Pennsylvania, Philadelphia, PA
D.A. Mankoff, University of Pennsylvania, Philadelphia, PA
A.C. Wolff, Johns Hopkins University, Baltimore Maryland

Document Type

Conference Proceeding

Publication Date

5-29-2024

Publication Title

Journal of Clinical Oncology

Abstract

Annual Meeting of the American Society of Clinical Oncology, ASCO 2024; May 31 - June 4, 2024; Chicago, IL

Volume

42

Issue

16

Comments

Abstract TPS614

Recommended Citation

Hennessy, M.; Gatsonis, C.; Jacene, H.; Connolly, R.M.; Burnette, B.L.; Stringer-Reasor, E.M.; Romanoff, J.; Taurone, A.; O'Sullivan, C.C.; Le-Petross, H.T.; Heath, C.L.; Stearns, V.; Fowler, A.M.; Tang, Shou-Ching; Sepulveda, K.; DeMichele, A.; Mankoff, D.A.; and Wolff, A.C., "Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial" (2024). School of Medicine Faculty Publications. 3055.
https://digitalscholar.lsuhsc.edu/som_facpubs/3055
10.1200/JCO.2024.42.16_suppl.TPS614